Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J-C., Carrasquillo MM., Abraham R., Hamshere ML., Pahwa JS., Moskvina V., Dowzell K., Jones N., Stretton A., Thomas C., Richards A., Ivanov D., Widdowson C., Chapman J., Lovestone S., Powell J., Proitsi P., Lupton MK., Brayne C., Rubinsztein DC., Gill M., Lawlor B., Lynch A., Brown KS., Passmore PA., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith AD., Beaumont H., Warden D., Wilcock G., Love S., Kehoe PG., Hooper NM., Vardy ERLC., Hardy J., Mead S., Fox NC., Rossor M., Collinge J., Maier W., Jessen F., Rüther E., Schürmann B., Heun R., Kölsch H., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Gallacher J., Hüll M., Rujescu D., Giegling I., Goate AM., Kauwe JSK., Cruchaga C., Nowotny P., Morris JC., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn PP., Van Broeckhoven C., Livingston G., Bass NJ., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw CE., Tsolaki M., Singleton AB., Guerreiro R., Mühleisen TW., Nöthen MM., Moebus S., Jöckel K-H., Klopp N., Wichmann H-E., Pankratz VS., Sando SB., Aasly JO., Barcikowska M., Wszolek ZK., Dickson DW., Graff-Radford NR., Petersen RC., Alzheimer's Disease Neuroimaging Initiative None., van Duijn CM., Breteler MMB., Ikram MA., DeStefano AL., Fitzpatrick AL., Lopez O., Launer LJ., Seshadri S., CHARGE consortium None., Berr C., Campion D., Epelbaum J., Dartigues J-F., Tzourio C., Alpérovitch A., Lathrop M., EADI1 consortium None., Feulner TM., Friedrich P., Riehle C., Krawczak M., Schreiber S., Mayhaus M., Nicolhaus S., Wagenpfeil S., Steinberg S., Stefansson H., Stefansson K., Snaedal J., Björnsson S., Jonsson PV., Chouraki V., Genier-Boley B., Hiltunen M., Soininen H., Combarros O., Zelenika D., Delepine M., Bullido MJ., Pasquier F., Mateo I., Frank-Garcia A., Porcellini E., Hanon O., Coto E., Alvarez V., Bosco P., Siciliano G., Mancuso M., Panza F., Solfrizzi V., Nacmias B., Sorbi S., Bossù P., Piccardi P., Arosio B., Annoni G., Seripa D., Pilotto A., Scarpini E., Galimberti D., Brice A., Hannequin D., Licastro F., Jones L., Holmans PA., Jonsson T., Riemenschneider M., Morgan K., Younkin SG., Owen MJ., O'Donovan M., Amouyel P., Williams J.
We sought to identify new susceptibility loci for Alzheimer's disease through a staged association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium (ADGC) in a companion paper. We undertook a combined analysis of four genome-wide association datasets (stage 1) and identified ten newly associated variants with P ≤ 1 × 10(-5). We tested these variants for association in an independent sample (stage 2). Three SNPs at two loci replicated and showed evidence for association in a further sample (stage 3). Meta-analyses of all data provided compelling evidence that ABCA7 (rs3764650, meta P = 4.5 × 10(-17); including ADGC data, meta P = 5.0 × 10(-21)) and the MS4A gene cluster (rs610932, meta P = 1.8 × 10(-14); including ADGC data, meta P = 1.2 × 10(-16)) are new Alzheimer's disease susceptibility loci. We also found independent evidence for association for three loci reported by the ADGC, which, when combined, showed genome-wide significance: CD2AP (GERAD+, P = 8.0 × 10(-4); including ADGC data, meta P = 8.6 × 10(-9)), CD33 (GERAD+, P = 2.2 × 10(-4); including ADGC data, meta P = 1.6 × 10(-9)) and EPHA1 (GERAD+, P = 3.4 × 10(-4); including ADGC data, meta P = 6.0 × 10(-10)).